Switching patients with inflammatory arthritis from Etanercept (Enbrel) to the biosimilar drug, SB4 (Benepali): A single-centre retrospective observational study in the UK and a review of the literature
Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2017;56(12):2093-101. [https://doi.org/10.1093/rheumatology/kex269][PMID: 28968793][PMCID: PMC5850652]
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4(10):e296. [https://doi.org/10.1371/journal.pmed.0040296]
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 2019;78:192-200. Epub 2018 Nov 5. [https://doi.org/10.1136/annrheumdis-2018-213474][PMID: 30396903]
Tweehuysen L, Huiskes VJB, van den Bemt BJF, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, et al. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study. Arthritis Rheumatol 2018;70(9):1408-18. Epub 2018 Aug 6. [https://doi.org/10.1002/art.40516][PMID: 29609207]
Lee SY, Szeto MCH, Galloway JB. Bio-similar to bio-originator switchback: not a reliable quality indicator. EULAR, Annual European Congress of Rheumatology 2018; Amsterdam, Holland. [Abstract no 1267] Ann Rheum Dis 2018;77:1727-8. [https://doi.org/10.1136/annrheumdis-2018-eular.5750]
Ma J, Petford S, Jones L, Douglas K, John H. Audit of the clinical efficacy and safety of etanercept biosimilar to its reference product in patients with inflammatory arthritis: experience from a district general hospital in the United Kingdom. BSR Annual Conference 2018; Liverpool, UK. [Abstract no 0447] Ann Rheum Dis 2018;77:1386. [https://doi.org/10.1136/annrheumdis-2018-eular.2498]
Rabbitts R, Jewell T, Marrow K, Herbison C, Laversuch C. Switching to biosimilars: An early clinical review. BSR Annual Conference 2017; Birmingham, UK. [abstract] [https://doi.org/10.1093/rheumatology/kex062.211]
Rajamani K, Choy E. Change in Disease Activity after Switching Etanercept (originator) to Biosimilar (Benepali) Is Associated with Active Disease at Baseline. ACR/ ARHP Annual Meeting 2018; Chicago, USA. [abstract]
Smith R, Fawthrop F. Similar experience of biosimilars: a review of Rotherham Hospital's experience of switching from enbrel to benepali. BSR Annual Conference 2018; Liverpool, UK. [abstract]
Alkoky H, Pakozdi A, Tahir H. Benepali Switches in Clinical Practice – a Positive Single Centre Experience. ACR/ARHP Annual Meeting 2018; Chicago, USA. [abstract]
Dyball S, Hoskins V, Christy-Kilner S, Haque S. Effectiveness and tolerability of Benepali in Rheumatoid Arthritis Patients switched from Enbrel. ACR/ARHP Annual Meeting 2017; San Diego, USA. [abstract]
Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs. 2018;32(5):397-404.